Table 8.
Logistic regression analysis for study of association between adverse events and dosage of MTX over 8 mg/week
| Variable | Estimated value of slope | Odds ratio | Lower bound (95% CI) | Upper bound (95% CI) | Significance (P value) |
|---|---|---|---|---|---|
| (A) Severe side-effect | |||||
| Cutoff | −4.2640 | 0.014 | 0.005 | 0.040 | 9.02E−16 |
| Group S1 versus group S5 | −0.0122 | 0.988 | 0.428 | 2.280 | 0.977 |
| Group S2 versus group S5 | 0.2976 | 1.347 | 0.882 | 2.057 | 0.169 |
| Group S3 versus group S5 | −0.0421 | 0.959 | 0.679 | 1.355 | 0.811 |
| Group S4 versus group S5 | −0.0179 | 0.982 | 0.761 | 1.268 | 0.891 |
| Sex | −0.1624 | 0.850 | 0.631 | 1.146 | 0.287 |
| Age | −0.0031 | 0.997 | 0.988 | 1.006 | 0.499 |
| BMI | 0.0029 | 1.003 | 0.967 | 1.040 | 0.874 |
| Steroid | 0.5566 | 1.745 | 1.337 | 2.277 | 0.0000412 |
| Folic acid | 0.1394 | 1.150 | 0.921 | 1.435 | 0.218 |
| Pulmonary diseases | 1.1545 | 3.172 | 2.051 | 4.908 | 2.16E−07 |
| Renal dysfunction | −0.5538 | 0.575 | 0.078 | 4.253 | 0.588 |
| DAS28 at phase A | 0.1901 | 1.209 | 1.107 | 1.321 | 0.000024 |
| (B) Severe + moderate side-effect | |||||
| Cutoff | −2.0443 | 0.129 | 0.074 | 0.226 | 5.51E−13 |
| Group S1 versus group S5 | 0.0279 | 1.028 | 0.662 | 1.597 | 0.901 |
| Group S2 versus group S5 | 0.1100 | 1.116 | 0.875 | 1.424 | 0.376 |
| Group S3 versus group S5 | 0.0685 | 1.071 | 0.897 | 1.278 | 0.448 |
| Group S4 versus group S5 | 0.0733 | 1.076 | 0.942 | 1.230 | 0.282 |
| Sex | 0.0312 | 1.032 | 0.872 | 1.220 | 0.716 |
| Age | −0.0035 | 0.996 | 0.992 | 1.001 | 0.152 |
| BMI | −0.0311 | 0.969 | 0.950 | 0.989 | 0.002 |
| Steroid | 0.5381 | 1.713 | 1.498 | 1.958 | 3.39E−15 |
| Folic acid | 0.3595 | 1.433 | 1.273 | 1.612 | 2.42E−09 |
| Pulmonary diseases | 0.6902 | 1.994 | 1.469 | 2.707 | 9.55E−06 |
| Renal dysfunction | 0.3250 | 1.384 | 0.625 | 3.066 | 0.423 |
| DAS28 at phase A | 0.1438 | 1.155 | 1.101 | 1.211 | 2.92E−09 |